- ASML is up about 3.5% in pre-market trading.
- The company beat expectations for operating profit, margin, and orders.
- Revenue forecasts for the rest of the year are boosting investor optimism.
- ASML is up about 3.5% in pre-market trading.
- The company beat expectations for operating profit, margin, and orders.
- Revenue forecasts for the rest of the year are boosting investor optimism.
ASML gains over 3.5% in pre-market trading after the company’s Q3 results exceeded investor expectations.
The excitement across the semiconductor sector is driven primarily by orders of €5.4 billion, above the forecast of €4.9 billion, confirming strong investment demand in artificial intelligence infrastructure. The Dutch company, as the only producer of EUV lithography machines needed for the most advanced AI chips, is one of the biggest beneficiaries of the sector’s investment boom.
Source: xStation5
CEO Christophe Fouquet highlighted the ongoing positive momentum in AI investments, extending to an increasing number of customers. The company plans to grow annual revenue to as much as €60 billion by 2030, up from €28.3 billion in 2024, and double its workforce near its headquarters in Veldhoven.
On the risk side, ASML faces primarily geopolitical challenges, including restrictions on sales to China resulting from U.S. actions targeting the Chinese semiconductor sector. The company is also preparing for possible supply disruptions due to China’s recent rare earth export restrictions. Considering ASML’s growing exposure to China, potential limits on AI development due to trade/technology tensions could impact the company’s projected revenue growth.
Key Q3 2025 Results
-
New orders: €5.40B (↓2.6% q/q), above forecast (€4.89B).
-
Net sales: €7.52B (↓2.3% q/q), below forecast (€7.71B).
-
System sales: €5.55B (↓6.3% q/q), slightly below expectations (€5.66B).
-
Total systems sold: 72 (below forecast 98.5); most units: ArFi (38).
-
China’s share of system sales: 42%, up from 27% in Q2.
-
-
Service & field operations sales: €1.96B, in line with forecast (€2.0B).
-
Gross margin: 51.6%, slightly above forecast (51.4%).
-
R&D expenses: €1.11B, below expectations (€1.2B).
-
Operating income: €2.47B, above forecast (€2.43B).
-
Operating margin: 32.8%, above forecast (31.3%).
-
Net income: €2.13B (↓7.2% q/q), slightly above forecast (€2.07B).
-
Cash and equivalents: €5.13B (↓29% q/q), below forecast (€5.91B).
-
Interim dividend: €1.60 per share.
Q4 2025 Outlook
-
Net sales: €9.2–9.8B (forecast: €9.23B).
-
Gross margin: 51%–53% (forecast: 50.7%).
-
R&D expenses: ~€1.2B (forecast: €1.25B).
TSMC Earnings Preview: Will the Key Semiconductor Supplier Surprise the Market?
US Open: American Indices Rally on Anticipated End of Fed Balance Sheet Reduction
Bank of America, Wells Fargo, and Morgan Stanley: Q3 2025 Earnings Overview
Abbott reports no surprises in Q3, but tariff risks and lowered forecasts drag the share price down💡
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
